Lilly Acquires Ventyx Biosciences for $1.2 Billion to Expand Inflammation Treatment Pipeline

Eli Lilly acquires Ventyx Biosciences for $1.2 billion to advance oral therapies targeting chronic inflammation in heart, brain, and autoimmune diseases.